Novartis AG
SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS
Last updated:
Abstract:
The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-coglycolide polymers (PLGAs).
Status:
Application
Type:
Utility
Filling date:
10 Mar 2020
Issue date:
2 Jul 2020